Group Ii Lp Column Sells 33,535 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stock

RAPT Therapeutics, Inc. (NASDAQ:RAPT) major shareholder Group Ii Lp Column sold 33,535 shares of the company’s stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $37.35, for a total value of $1,252,532.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Ii Lp Column also recently made the following trade(s):

  • On Monday, September 13th, Group Ii Lp Column sold 14,317 shares of RAPT Therapeutics stock. The shares were sold at an average price of $35.27, for a total value of $504,960.59.
  • On Friday, September 10th, Group Ii Lp Column sold 21,738 shares of RAPT Therapeutics stock. The shares were sold at an average price of $35.19, for a total value of $764,960.22.
  • On Monday, August 23rd, Group Ii Lp Column sold 68,340 shares of RAPT Therapeutics stock. The stock was sold at an average price of $31.34, for a total value of $2,141,775.60.
  • On Friday, August 20th, Group Ii Lp Column sold 4,539 shares of RAPT Therapeutics stock. The stock was sold at an average price of $30.08, for a total value of $136,533.12.

Shares of RAPT Therapeutics stock opened at $39.47 on Friday. The firm has a market capitalization of $1.16 billion, a PE ratio of -16.38 and a beta of 0.04. RAPT Therapeutics, Inc. has a twelve month low of $14.63 and a twelve month high of $43.26. The firm’s 50-day moving average price is $33.02 and its 200 day moving average price is $26.71.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Wednesday, August 11th. The company reported ($0.63) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.68) by $0.05. RAPT Therapeutics had a negative net margin of 1,219.06% and a negative return on equity of 45.84%. On average, equities analysts anticipate that RAPT Therapeutics, Inc. will post -2.64 EPS for the current fiscal year.

Several equities research analysts have weighed in on RAPT shares. Cantor Fitzgerald increased their price target on RAPT Therapeutics from $51.00 to $71.00 and gave the stock an “overweight” rating in a research report on Monday, June 14th. Piper Sandler started coverage on shares of RAPT Therapeutics in a research note on Sunday, June 20th. They set an “overweight” rating and a $61.00 target price on the stock. Roth Capital increased their target price on shares of RAPT Therapeutics from $38.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, June 14th. Wells Fargo & Company increased their target price on shares of RAPT Therapeutics from $30.00 to $65.00 and gave the stock an “overweight” rating in a research note on Monday, June 14th. Finally, Zacks Investment Research raised shares of RAPT Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 11th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $59.86.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its holdings in shares of RAPT Therapeutics by 39.3% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,593,399 shares of the company’s stock worth $114,234,000 after buying an additional 1,013,553 shares during the last quarter. Perceptive Advisors LLC increased its holdings in RAPT Therapeutics by 57.1% in the 1st quarter. Perceptive Advisors LLC now owns 2,477,481 shares of the company’s stock valued at $55,000,000 after purchasing an additional 900,000 shares during the last quarter. BlackRock Inc. increased its holdings in RAPT Therapeutics by 15.6% in the 2nd quarter. BlackRock Inc. now owns 1,608,662 shares of the company’s stock valued at $51,141,000 after purchasing an additional 217,382 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of RAPT Therapeutics by 21.6% in the second quarter. Vanguard Group Inc. now owns 913,916 shares of the company’s stock worth $29,054,000 after acquiring an additional 162,516 shares in the last quarter. Finally, Ghost Tree Capital LLC acquired a new position in shares of RAPT Therapeutics in the second quarter worth $18,120,000. Institutional investors and hedge funds own 87.57% of the company’s stock.

About RAPT Therapeutics

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Featured Article: Moving Average (MA)

Insider Buying and Selling by Quarter for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.